Alpa Laboratories Past Earnings Performance
Past criteria checks 5/6
Alpa Laboratories has been growing earnings at an average annual rate of 39.6%, while the Pharmaceuticals industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 7% per year. Alpa Laboratories's return on equity is 12.5%, and it has net margins of 15.5%.
Key information
39.6%
Earnings growth rate
39.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 7.0% |
| Return on equity | 12.5% |
| Net Margin | 15.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Alpa Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,148 | 178 | 135 | 0 |
| 30 Sep 23 | 1,148 | 185 | 132 | 0 |
| 30 Jun 23 | 1,054 | 130 | 124 | 0 |
| 31 Mar 23 | 930 | 126 | 125 | 0 |
| 31 Dec 22 | 1,007 | 45 | 121 | 0 |
| 30 Sep 22 | 1,022 | 48 | 121 | 0 |
| 30 Jun 22 | 1,113 | 103 | 118 | 0 |
| 31 Mar 22 | 1,123 | 141 | 123 | 0 |
| 31 Dec 21 | 1,121 | 156 | 116 | 0 |
| 30 Sep 21 | 1,159 | 139 | 125 | 0 |
| 30 Jun 21 | 1,128 | 105 | 121 | 0 |
| 31 Mar 21 | 976 | 72 | 120 | 0 |
| 31 Dec 20 | 907 | 69 | 126 | 0 |
| 30 Sep 20 | 817 | 58 | 118 | 0 |
| 30 Jun 20 | 821 | 39 | 115 | 0 |
| 31 Mar 20 | 860 | 19 | 122 | 0 |
| 31 Dec 19 | 869 | 9 | 129 | 0 |
| 30 Sep 19 | 888 | 6 | 128 | 0 |
| 30 Jun 19 | 817 | 11 | 127 | 0 |
| 31 Mar 19 | 780 | 10 | 126 | 0 |
| 31 Mar 18 | 628 | 28 | 106 | 0 |
| 31 Mar 17 | 635 | 25 | 89 | 0 |
| 31 Mar 16 | 536 | 68 | 99 | 0 |
| 31 Mar 15 | 574 | -14 | 88 | 0 |
| 31 Dec 14 | 618 | -19 | 136 | 0 |
| 30 Sep 14 | 627 | -46 | 138 | 0 |
| 30 Jun 14 | 573 | -60 | 138 | 0 |
| 31 Mar 14 | 567 | -52 | 135 | 0 |
| 31 Dec 13 | 566 | -66 | 119 | 0 |
| 30 Sep 13 | 539 | -84 | 118 | 0 |
| 30 Jun 13 | 523 | -61 | 111 | 0 |
Quality Earnings: 532878 has high quality earnings.
Growing Profit Margin: 532878's current net profit margins (15.5%) are higher than last year (4.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532878's earnings have grown significantly by 39.6% per year over the past 5 years.
Accelerating Growth: 532878's earnings growth over the past year (297.5%) exceeds its 5-year average (39.6% per year).
Earnings vs Industry: 532878 earnings growth over the past year (297.5%) exceeded the Pharmaceuticals industry 23.3%.
Return on Equity
High ROE: 532878's Return on Equity (12.5%) is considered low.